ArticleJACC. Case reports2026
Balloon-Assisted Anterior Mitral Leaflet Translocation for Valve-in-MAC Transcatheter Mitral Valve Replacement.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Expanding Transcatheter Mitral Valve Replacement Eligibility for ViMAC With a Streamlined BATMAN Leaflet Modification Technique.JACC. Case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere mitral annular calcification (MAC) complicates transcatheter mitral valve replacement (TMVR) by increasing left ventricular outflow tract (LVOT) obstruction risk. Balloon-assisted translocation of the anterior mitral leaflet (BATMAN) may reduce this risk, but experience with native valve-in-mitral annular calcification (ViMAC) remains limited. CASE SUMMARY: Eleven high-risk patients with symptomatic severe native mitral annular calcification (81.8% NYHA functional class III/IV; predicted neo-LVOT 196.3 ± 88.8 mm DISCUSSION: Published BATMAN reports support feasibility, but ViMAC-specific data are limited. This series addresses high-risk anatomy with few alternatives and substantial early hazard. TAKE-HOME MESSAGES: BATMAN-facilitated ViMAC TMVR appears feasible without technique-related adverse events, but early mortality remains substantial. Use requires multidisciplinary selection and shared decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.